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ABSTRACT
Currently, there are no biomarkers for Chikungunya fever (CHIK) in clinical practice that 
can accurately predict the severity or chronification of the disease. The aim of this study is 
to evaluate the existing literature on biomarkers related to the severity and chronification of 
CHIK. In this sense, a systematic review was conducted based on the PRISMA Statement 
guideline. Articles that described the association of biomarkers with the evolution of the 
disease (severity or chronification), published until August 20th 2019 were considered 
eligible. The search was carried out in the PubMed, Scopus, Virtual Health Library (VHL) 
and Science Direct databases. After searching the databases, 17 articles were added to the 
review, and after analyzing the articles, several biomarkers were associated with severity, 
such as increased levels of IL-6, IP-10, IL-1b, MIG, MCP-1, and reduced levels of RANTES 
and IL-8 or chronification, such as increased levels of IL-6, TNF-α, MCP-1, IL-12, INF-α, 
IL-13, INF-γ, GM-CSF, CRP, IL-1a, IL-15, Factor VII, IP-10, IL-10, IL-4, IL-1RA, IL-8, 
MIP-1α, MIP-1β, ferritin, MIG, ESR, NO, malondialdehyde, and reduced levels of RANTES, 
ferritin, eotaxin, HGF, IL-27, IL-17A, IL-29, TGF-β, IL-10, and thiols. IL-6, CRP and TNF-α 
were included in the meta-analysis to assess the relationship with chronification, although 
they did not reach statistical significance. It was concluded that several biomarkers showed 
a relationship with severity and chronification of CHIK; the search for these biomarkers can 
reveal prognostic factors and important therapeutic targets for the treatment of the disease. 
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INTRODUCTION
Arboviruses such as dengue, yellow fever, zika, West Nile fever and Chikungunya 
fever (CHIK) have caused several outbreaks throughout history, and their 
geographical expansion has caused human and financial losses, becoming today 
one of the major global public health problems. This expansion can be explained 
by the increase in the global displacement of people, adaptation of vectors and 
failure to contain epidemics1.
The Chikungunya virus (CHIKV), originally described in Tanzania2, had several 
isolated outbreaks in Africa, and since 2004, a major epidemic started off the coast 
of Kenya, and spread to numerous islands in the Indian Ocean, India and Asia3. 
CHIKV maintained a trend towards geographic expansion, reaching the Americas, 
having its first record on the continent in 20134.
CHIK fever is transmitted by mosquitoes of the genus Aedes. The disease 
manifests with a sudden onset of high fever, cutaneous rashes and severe arthralgia, 
arthritis, myalgia, headaches and photophobia. Most of the time, it is self-limited, but 
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it can evolve to severe conditions5. In addition to its potential 
severity, CHIK fever can progress to chronification. The 
most common chronic manifestations are musculoskeletal 
and long-term rheumatic disease, which lead to a worsening 
of the patients’ quality of life6.
In the acute phase of the disease, several cytokines 
are increased such as interleukin 6 (IL-6), tumor necrosis 
factor alpha (TNF-a), granulocyte macrophage-colony 
stimulating factor (GM-CSF), macrophage inflammatory 
protein-1 (MIP-1), and monocyte chemoattraction protein-1 
(MCP-1); while in convalescence, lower levels of these 
cytokines were observed7. However, in clinical practice, 
there is no cytokine or other type of biomarker routinely 
used to predict the evolution of CHIK fever to severe or 
chronic conditions.
Considering the expansion of the disease and its 
potential to evolve to severe cases and chronification, the 
identification of biomarkers that can predict the outcome 
of the disease is of great importance. In this context, this 
systematic review was conducted to identify the existence 
of biomarkers related to the severity and chronification of 
CHIKV fever.
MATERIAL AND METHODS
This systematic review was carried out based on the 
Preferred Reporting Items for the Systematic Reviews 
and Meta-Analyzes guideline-The PRISMA Statement8, 
seeking to evaluate the hypothesis that biomarkers can 
predict the evolution (severity or chronification) of the 
CHIKV fever. This systematic review was registered on the 
PROSPERO platform under Nº CRD42018094407.
The search for data was carried out in the PubMed, 
Scopus, Virtual Health Library (VHL), and Science Direct 
databases including studies published until August 20th 2019 
without restricting the initial data collection period, since 
the objective was to recover the maximum available items.
The search strategy used PubMed and Scopus to select 
the option “advanced search”, “title/abstract” to search 
for the keyword Chikungunya with the Boolean operator 
AND associating the keywords marker and markers, in turn 
linked by the operator OR, in the “All Fields” option. In the 
Science Direct database the same keywords were used, but 
the Research Articles filter was added, while in the VHL 
database, the option “title, summary and subject“ was used 
to search for Chikungunya AND marker OR markers.
After selecting articles in each database, duplicate 
publications were excluded. The search was carried out 
initially by two researchers (ASF and NRB) reading the 
abstracts independently, to avoid the presence of bias in 
the selection and exclusion of studies. After selection, in 
case of disagreement between the two reviewers, a third 
and fourth (CLO, CSC) researchers defined the relevance 
of the abstracts, considering the aims of the investigation. 
To detect any relevant scientific evidence that may not have 
been identified by the search strategy, a search for articles 
was also carried out in the reference list of studies and 
included in the review.
The articles that met the inclusion criteria were read in 
full. The collected variables regarding the characteristics 
of the studies were: name of the first author, year of 
publication, study reference, study location, language, 
type of study, sample size, age group, gender, outcome, 
biomarkers used, study result and laboratory method for 
analyzing the biomarkers.
To assess the quality of the studies included in this 
review, the Strengthening Reporting of Observational 
studies in Epidemiology (STROBE) guideline was used. 
In this methodology, a scale ranging from 0 to 22 is used, 
and the higher the score the higher the quality9.
Meta-analysis
After determining the biomarkers related to chronification 
and severity, it was decided not to perform a meta-analysis 
related to severity due to different criteria for defining the 
term used by each study.
Chronification-related biomarkers, which had data 
available in more than two studies, were used for meta-
analysis, comparing their mean levels and the studies 
controls.
When relevant data were not found, the authors 
were contacted by email, and in cases in which there 
was no success in obtaining the information, the article 
was excluded from the meta-analysis. After excluding 
studies with incomplete data, and evaluating the available 
biomarkers, studies that addressed TNF-α, IL-6 and CRP 
were included in the meta-analysis. The mean value of the 
biomarker, its standard deviation, and number of patients 
in the chronification group and study control group were 
collected, and meta-analysis was performed to compare 
the mean difference (MD) of the biomarker between the 
groups. To create forest plots, we calculated the weighted 
mean difference (WMD) with 95% confidence intervals 
(95% CIs). Analyzes were performed using the fixed effects 
model and the random effects model. 
The studies included in the meta-analyzes performed 
the collection of biomarkers at different times during the 
natural history of the disease (acute or chronic phase) 
and had different control groups, and to try to control the 
impact of these, each meta-analysis describes the moment 
of collection and the control group used. In the case of 
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IL-6, it was possible to analyze two variations of the meta-
analysis, one grouping studies in which sample collections 
were carried out in both phases (acute and chronic), and 
one only with studies performed during the chronic phase. 
The PCR metanalysis covered chronic phase studies and 
the TNF-a metanalysis used studies carried out during both 
phases of the disease.
The I2 index, (I2) and the chi-square test was performed 
to test the heterogeneity among the included studies. A 
P  value < 0.05 was considered statistically significant. 
I2 > 50% was considered indicative of a high heterogeneity.
One study presented the means, but did not provide 
standard deviations, thus we performed the imputation 
of values using the highest value among the studies that 
addressed the biomarker to obtain a more conservative 
result.
Additionally, we performed a meta-analysis to calculate 
the pooled prevalence with 95% CI to assess the percentage 
of chronification in studies that followed-up patients from 
the acute phase and measured the presence of persistent 
symptoms. Articles that had a loss of follow-up greater than 
50% of the sample were excluded to reduce the chance of 
bias. The R® software with the R Studio® interface were used 
to perform all the statistical analyzes through the meta and 
metafor packages, using metaprop and metacont commands.
RESULTS
The search strategy resulted in the identification of 
104 articles in the PUBMED database, 478 in Scopus, 
463 in Science Direct and 92 in the VHL, totaling 
1,137  manuscripts. In addition, 385 abstracts from the 
references of selected articles were evaluated to allow 
them to enter the systematic review. After removing the 
duplications, 1,281 studies remained, and their titles and 
abstracts were read resulting in 30 articles selected by two 
reviewers, independently (ASF & NRB). The divergences 
were assessed by a third and fourth reviewers (CLO & CSC) 
who excluded five articles because they were considered 
outside the context of the guiding question (three did not 
address biomarkers, two were reviews). In total, 25 articles 
were read in full and after reading them, eight articles were 
excluded. Among the articles excluded after full reading, 
two were case reports, two did not address chronification or 
severity of the disease, and four did not address biomarkers 
(Figure 1).
Of the 17 (100%) articles included in the review, 
13 (76%) addressed chronification10,11-22, three articles (18%) 
addressed severity23-25 and one article (6%) addressed both 
themes26. Eleven cohort studies10,12-14,16,17,19,21,22,24,26, two 
case-control studies15,18 and four sectional studies11,20,23,26 
were included. The cohort studies had follow-up times 
ranging from 1 to 36 months, samples came from India 
(7 studies)10,11,15,17,21,22,26, Singapore (three studies)13,16,23, 
France (two studies)12,14, Curacao Island18, Mexico19, 
Italy24, Thailand25 and Brazil20 (one from each country). 
These publications took place between 2009 and 2019, 
samples were heterogeneous, the age groups ranged from 
19 to 90 years. The proportion of patients of each gender 
also varied, with the percentage of men ranging from 44% 
to 100%. (Table 1). The samples size ranged from 10 to 
573 participants. 
Biomarkers were measured during the acute phase of 
disease in six studies10,18,21,23,25,26, in the subacute/chronic 
phase in four articles12,13,15,20, and was measured in both 
phases in seven studies11,14,16,17,19,21,24. The control group 
used in each study has also varied, with seven studies 
using healthy patients10,15,17,20,22-24, two used patients with 
other febrile diseases18,25, and eight used patients who had 
CHIK fever, however they had no symptoms in the chronic 
phase11-14,16,19,21,26 (Table 2 and Table 3).
The criterion for defining severity of CHIKV fever has 
also varied, and two studies considered as a severe CHIKV 
fever patient those who had a temperature > 38.5  ºC or 
heart rate > 100 beats/minute, or platelet count below 
100 x 109 g/L23,25. Another study evaluated the severity of 
arthritis through a visual analog scale26 and a survey defined 
the severity from a questionnaire, created by the authors, 
which quantified the symptoms24. The persistent symptom 
Figure 1 - Flowchart of articles selection based on PRISMA 
guidelines.
Ferreira et al.
Rev Inst Med Trop São Paulo. 2021;63:e16Page 4 of 11
accompanied by most studies to define subacute or chronic 
disease was arthralgia, but other symptoms such as arthritis, 
fatigue, myalgia and low back pain were also assessed.
The biomarkers covered in the studies were leukocyte, 
lymphocyte and platelet count, liver enzymes dosage, 
serum creatinine, hemoglobin, haptoglobin, ferritin, 
fibrinogen, VHS, lactic dehydrogenase (LDH), CRP, IL-1, 
IL-1a, IL-1RA , IL-1b, IL-2, interleukin -3 (IL-3), IL-4, 
IL-5, IL-6, interleukin-7 (IL-7), IL-8, IL-10, IL-12, IL-13, 
IL-15, IL-17, IL-18, interleukin-21 (IL-21), interleukin-22 
(IL-22), interleukin-23 (IL-23), interleukin-27 (IL- 27), 
interleukin-29 (IL-29), IL-1ra, INF-α, INF-γ, TNF-α, 
TNF-b, tumor necrosis factor receptor 2 (TNFR2), 
MCP-1, IP-10, MIG, CC ligand 5 chemokine regulated 
by expressed activation and secreted by normal T cells 
(RANTES), eotaxin, GM-CSF, hepatocyte growth factor 
(HGF), transforming growth factor beta (TGF-β), factor 
VII, C3, anti-cyclic citrullinated peptide (anti-CCP), 
rheumatoid factor (FR), anti-nuclear antibody (Anti-ANA), 
Von Willebrand factor, neopterin, matrix metalloproteinases 
(MMP), tissue inhibitor of metalloproteinases 1 (TIMP-1), 
MIP-1α, epidermal growth factor (EGF), HGF, FGF-b, 
VEGF, G-CSF, GM-CSF, MIP-1β, vascular cell adhesion 
molecule 1 (VCAM-1), intercellular adhesion molecule 1 
(ICAM-1), vitamin D carrier protein (DBP), alpha-2-
macroglobulin, alpha-1-antitrypsin (AAT), beta-2-
microglobulin (B2M), brain-derived neurotrophic 
factor (BDNF), stem cell factor antagonist, nitric acid 
(NO), carbonylated protein, thiols and malondialdehyde 
(Figure 2).
Chronification was associated with increased levels 
of IL-6 (6 studies)10,11,15,16,19,22, TNF-α (2 studies)10,15, 
MCP-1 (3 studies)10,11,17, IL-1214, INF-α14, IL-1315, INF-γ15, 
GM-CSF16, CRP12, IL-1a12, IL-1512, Factor VII12, IP-1010, 
IL-1010, IL-410, IL-1RA11, IL- 811, MIP-1α11, MIP-1β11, 
ferritin18, MIG17, ESR19, NO21, malondialdehyde21 and 
with reduced levels of RANTES11,17, ferritin12, eotaxin16, 
HGF16, IL-2720, IL-17a20, IL-2920, TGF-β21, IL-1021, and 
thiols21 (Figure 2).
Among the increased biomarkers that showed an 
association with severity were increased levels of IL-6 
(2  studies)23,25, IP-10 (2 studies)23,24, IL-1b23, MIG24, 
MCP-125 and reduced levels of RANTES23, and IL-825 
(Figure 2).
Among the articles included in the meta-analysis, the 
methodology used in each study to measure biomarkers 
has greatly differed, using Enzyme Linked Immunosorbent 
Assays (ELISAs)14,15,19 or the Multiplex Kit – Luminex16 
for measuring cytokines, and in the case of measuring CRP 
one study cited the use of protein electrophoresis12.
The studies had scores between 19 and 13 on the 
STROBE scale; the score of 19 was obtained by three 
Table 1 - Comparative analysis between articles according to the designs of the studies and characteristics of the evaluated 
populations (n = 13).
Study Outcome Location Study design
Time of 
follow-up
Age range Mean age
Gender 
(M/F)
Win et al.13 Chronification Singapore Cohort 1.5 months 20-79 37 75/22
Hoarau et al.14 Chronification France Cohort 12 months 19-90 60,3 19/30
Chopra and Venugopalan15 Chronification India Case control NA NI NI 54/74*
Chow et al.16 Chronification Singapore Coorte 2 to 3 months 23-67 39 26/4
Chaaitanya et al.11 Chronification India Sectional NA 25-55 34.5 NI
Chopra et al.22 Chronification India Cohort 24 months NI NI 226/282***
Schilte et al.12 Chronification France Cohort 36 months NI NI 73/74***
Reddy et al.17 Chronification India Cohort 3 months 21–80 40,6 31/17
Venogopalan et al.10 Chronification India Cohort 1 month NI 36 44/66*****
Anfasa et al.18 Chronification Curaçao Island Case control NA NI NI NI
Sepúlveda-Delgado et al.19 Chronification Mexico Cohort 12 months 27-68 48 4/6
Banerjee and 
Mukhopadhyay21
Chronification India Cohort 0.33 a 1 month 35-76* 55* 10/15*
Cavalcanti et al.20 Chronification Brazil Sectional NA NI 55.2 8/37
Ng et al.23 Severity Singapore Sectional NA 22-65 35 10/0
Kelvin et al.24 Severity Italy Cohort 12 months NI NI NI
Lohachanakul et al.25 Severity Thailand Sectional NA NI 34.9** 23/39******
Jain et al.26 Severity/
Chronification
India Cohort 3 months 17-69 36 282/291
*Considering only samples with chronic symptoms** Considering only samples with severe symptoms; ***Considering the follow-
up of 14 months; **** Estimated value; *****Estimated value considering only samples with chronic symptoms; ****** Considering 
patient with or without chikungunya; M = Male; F = Female; NI = Not informed; NA = Not applicable
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studies10,12,23, 18 points by four other studies14,21,22,24, 
17 points by five studies11,13,18,19,26, 16 points by four 
studies15,16,20,25, and one study obtained 13 points17; the 
average of score was 17. No article achieved the maximum 
score.
Meta-analysis
The assessment of IL-6 levels in the meta-analyzes that 
grouped studies with patients who evolved to chronicity 
at any stage of the disease (acute or chronic phase) 
(MD  =  -7.65/95% CI -34.06 - +18 , 17) or only in the 
chronic phase (MD = -2.90/95% CI -35.74 - +29.94), in 
both cases there was no statistically significant difference 
in comparison with healthy patients or patients with a 
previous history of Chikungunya without chronification. 
Additionally, the evaluation of CRP in the chronic 
phase (MD = -2.70/95% CI -16.93-+11.54) and the 
evaluation of TNF-a at any stage of the disease (MD = 
-1.91/95% CI -33.19-+37.01) did not show any statistically 
significant difference when compared to the control group 
(Figure 3).
Table 2 - Comparative analysis between articles that addressed chronification according to the sample size, chronification index, 





biomarkers in the 





Collection time in the 
group with persistent 
symptoms
Win et al.13 97 14 Cases without 
chronification
25 Chronic phase
Hoarau et al.14 49 6 Cases without 
chronification*
9 Acute and chronic 
phase
Chopra and Venugopalan15 141 141 Healthy patients 80 Chronic phase
Chow et al.16 30 4 Cases without 
chronification*
26 Acute and Chronic 
phase
Chaaitanya et al.11 22 10 Cases without 
chronification*
6 Chronic phase**
Chopra et al.22 509 22*** Healthy patients NI Acute and chronic 
phase
Schilte et al.12 180 20 Cases without 
chronification
22 Chronic phase
Reddy et al.17 48 4 Healthy patients 37 Acute and chronic 
phase
Venogopalan et al.10 509 132 Healthy patients 80 Acute phase
Anfasa et al.18 116 116 Febrile patients 
without CHIK
25 Acute phase
Sepúlveda-Delgado et al.19 10 6 Cases without 
chronification
4 Acute and chronic 
phase




Cavalcanti et al.20 45 21 (chronic)/ 
24 (subacute)
Healthy patients 49 Subacute/chronic 
phase
Jain et al.26 572 40 Cases without 
chronification
27 Acute phase
*Additional analysis with a control group of healthy patients; **Collection at 10th month; ***Considering the follow-up of 18 to 24 months.
Table 3 - Comparative analysis between the articles that addressed severity according to the sample size, collection time and 








Ng et al.23 10 5 Healthy patients 9 Acute phase
Kelvin et al.24 50 14 Healthy patients 10 Acute and chronic phase
Lohachanakul et al.25 62 15 Febrile patients without CHIK 27 Acute phase
Jain et al.26 573 40 Cases without severe arthralgia 27 Acute phase
Ferreira et al.
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The proportion of chronification considering only cohort 
studies that followed patients from the acute phase was 15% 
(95% CI, 0.08-0.26) of chronification among patients who 
had CHIK fever (Figure 4).
The heterogeneity was statistically significant in the IL-6 
meta-analyzes measured in the chronic phase (I2 = 72%, 
P = 0.03), in the evaluation of CRP (I2 = 74%, P = 0.02), and 
in the assessment of the proportion of the chronic (I2 = 87%, 
P = 0.01). In addition, the meta-analyzes that evaluated IL-6 
in any stage of the disease (I2 = 57%, P = 0.07) and in the 
meta-analysis that evaluated TNF-α (I2 = 59%, P = 0.09) 
showed high I2 values.
DISCUSSION
Although the meta-analyzes did not show statistically 
significant relationships, several studies cited biomarkers 
related to the severity and chronicity of the disease, especially 
the main biomarkers associated with chronification, being 
IL-6, TNF-α and MCP-1. These biomarkers may have a 
potential use as therapeutic targets or prognostic markers 
in future studies. Another relevant finding is that other 
biomarkers widely used and easily accessible in practice, 
such as liver enzymes, renal function and antibodies did 
not show a relationship with the evolution of the disease. 
Research on the topic is still scarce so that it is possible that 
with the increase in the number of studies and the analysis 
of larger samples, the statistical associations will become 
more notorious and other associations will be discovered, 
proven or refuted.
Many studies evaluated the association with ILs and 
chronification, among them IL-6 was related to chronification 
by six studies10,11,15,16,19,22, Chopra and Venugopalan15 evaluated 
patients with persistent symptoms after one year of illness and 
observed a marginal increase in IL-6, IFN-γ, TNF-α and IL-13, 
a finding that according to the authors, may suggest an ongoing 
immune inflammatory process. Chopra et al.22 found an 
eight-fold increment of IL-6 values in patients in comparison 
with the healthy control group and IL-6 remained elevated 
during the two-year follow-up period; the researcher argued 
that the increased levels may be related to viral persistence. 
Sepulveda-Delgado et al.19 observed patients with high levels 
of IL-6 at the time of diagnosis and ESR developed subacute 
or chronic disease, but the study conducted by Hoarau et al.14 
found no differences, in the acute phase, between patients who 
progressed or not to chronification in most analyzes, but the 
levels of circulating IL-12 persisted high for months only in 
the group that evolved to chronicity. In the study conducted by 
Chow et al.16 patients with persistent arthralgia had increased 
levels of IL-6 and GM-CSF, while those who recovered had 
normal levels. In contrast, patients who did not have persistent 
arthritis had higher levels of HGF, a hormone that facilitates 
cartilage repair, and eotaxin, a cytokine that indicates the 
presence of a local anti-inflammatory response. 
Banerjeeet and Mukhopadhyay21 evaluated inflammatory 
and oxidative stress parameters in patients with CHIK and 
observed that high levels of IL-6 and INF-γ are related to 
the presence of reactive oxygen species (ROS). The study 
also observed that in the group with persistent arthritis, the 
levels of malondialdehyde (marker of lipid peroxidation), 
and nitric oxide (NO) were increased in relation to controls, 
and the levels of thiols (important agents of enzymatic 
Figure 2 - Chart showing the relationship of the biomarkers addressed with severity or chronification of CHIKV fever according to 
the authors’ assessments.
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activity that can reduce damage caused by the oxidative 
stress) were reduced in patients with persistent symptoms, 
showing a tendency towards a greater oxidative stress in 
this group of patients. In turn, free radicals continuously 
Figure 3 - Comparative meta-analyzes of biomarkers related to chronification of CHIKV fever. 
Figure 4 - Meta-analysis on the percentage of chronification among studies used in the systematic review.
Ferreira et al.
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increase the availability of neoantigens, which possibly 
causes more oxidative damage, including joint damage, 
and the development of persistent polyarthralgia. Another 
interesting finding of this research was that the anti-
inflammatory interleukin IL-10 was significantly reduced 
in the group with persistent arthralgia. The authors related 
these reduced levels to the presence of decreased numbers of 
regulatory T cells in a patient with polyarthralgia secondary 
to CHIKV, and in turn these cells are IL-10 producers.
The study conducted by Cavalcanti et al.20 compared a 
patient with CHIK fever in the subacute or chronic phase 
with healthy people and observed increased levels of IL-27, 
IL-17A, IL-29 and TGF-β in sick patients. The levels of 
IL-27 were significantly higher in patients in the chronic 
phase, when compared to those in the subacute phase, and 
the authors propose that IL-27 production can be initiated 
with antigen presenting cells of monocytic/macrocytic 
strains, which can act in CHIK fever as reservoirs of 
the virus or as catalysts in the inflammation process. In 
addition, IL-27 can also act in a pro-inflammatory way, 
down regulating the response of regulatory T cells (Tregs) 
increasing the Th1 or the Th17 responses in the absence of 
STAT1. In the study by Chaaitanya et al.11, the cytokines 
IL-1RA, IL-6, IL-8, MIP-1a, MIP-1b and MCP-1, showed 
elevated levels in patients with chronic arthropathy after 
CHIKV infection compared with healthy patients. The study 
has also shown that in the acute phase the levels of IL-1RA 
and IL-6 are high, however the level of IL-6 observed in 
chronic patients was much higher than those of acute phase 
patients, indicating its strong association with chronic 
arthritis in patients infected by CHIKV.
MCP-1 has been related to chronification in three 
studies10,11,17. Reddy et al.17 reported that patients with 
persistent arthralgia had high values of IL-1b, IL-4, IL-6, 
IL-8, IP-10, MCP-1 and MIG during the second week 
of illness and reduced levels of RANTES. The authors 
highlighted the chemotactic function of activation and 
migration of MCP-1 macrophages in the mechanism of 
induction of joint injury. Venogopalan et al.10 observed 
that cytokines, particularly TNF-a, MCP-1, IL-4, IL-6 
and IL-10 showed maximum levels in the extended 
symptomatic phase and remained high in recovered 
subjects. Additionally, they found a relationship between 
the increase in IL-6, IP-10, CRP levels and the persistence 
of CHIKV musculoskeletal pain. In addition, an early and 
intense response of IFN-α, IFN-β and IFN-γ was associated 
with persistent symptoms; the authors associated this 
response with a failure of the host to eradicate the virus. 
Chaaitanya et al.11, found that the levels of IL-8, MCP-1, 
MIP-1a and MIP-1b were much higher in patients with 
chronic arthritis compared to controls, acute patients and 
patients who had fully recovered. In addition, reduced levels 
of RANTES have also been observed in chronic patients; 
MCP-1 acted as a chemotactic factor for monocytes27, in 
turn monocytes and macrophages played an important role 
in the pathophysiology of arthritis28. 
TNF-α has also been correlated to chronification in 
two studies10,15. TNF-α is a cytokine mainly induced by 
macrophages, has a chemotactic effect on several leukocyte 
populations, is involved in the process of inflammation 
onset, is an important innate immunity component and has 
also been related to the pathophysiology of rheumatoid 
arthritis29.
The immune response and the Th1 or Th2 profile 
manifested by individuals can also be related to the cytokine 
profile found. Elevated levels of Th2 cytokines have been 
associated with prolonged musculoskeletal symptoms 
(IL-4, IL-6, and IL-10)10. Another factor to be considered is 
that the high viral load was related to the chronicity of the 
disease; high viral load was associated by Chow et al.16 with 
levels of IFN-a, IL-6, IL-12, IL-1RA, IP-10 and MCP-1. 
Similarly, in the study by Reddy et al.17, MCP-1 strongly 
correlated and IL-6 moderately correlated with high viral 
load in patients in the acute phase of CHIKV fever.
The association of CRP with chronification has 
been found in some studies. In the study conducted by 
Schilte et al.12, CRP levels tended to be higher in patients 
with persistent arthritis. Hoarau et al.14 observed that 
patients who progressed to chronification presented a 
high level of CRP when compared to healthy controls. 
Chow et al.16 observed high levels of CRP during the acute 
phase patients who evolved to chronicity, when compared 
with those of healthy controls and recovered patients. 
The authors suggested that CRP, due to its low cost, high 
availability, and because it is related to increased levels 
of viral load, could help in the early identification and 
monitoring of patients with CHIK at risk of serious disease.
Other factors have been considered in some studies, 
such as creatinine levels and ferritin. Win et al.13 observed 
that creatinine was significantly lower in patients with 
persistent arthralgia, but it was more prominent in women, 
however women had lower levels of creatinine, which 
could explain this result. In the same study, there was a 
tendency of thrombocytopenia and high levels of liver 
enzymes associated with slow recovery from joint pain. 
Regarding ferritin, Anfasa et al.18 found an association 
between increased serum ferritin in the acute phase of the 
disease and prolonged arthralgia. In addition, they have 
also associated increased levels of ferritin with increased 
neopterin, which is a specific marker of macrophage 
activation. Increased levels of ferritin and neopterin are 
markers of macrophage activation, and ferritin synthesis 
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can be triggered by cytokines and iron; the study showed 
that increased ferritin was associated with the absence 
of viremia. Macrophages and hepatocytes are producers 
and secretors of ferritin, in turn the production of this 
compound can be activated during viral replication. 
Conversely, Schilte et al.12 found a relationship between 
low levels of ferritin and the chronification of the disease. 
The divergences in the findings do not allow a conclusion 
to be drawn, and further studies are needed to assess the 
true impact of ferritin in CHIKV fever.
The profile of biomarkers of patients who progressed 
with persistent symptoms changed when assessed at the 
beginning of the disease onset compared to the period 
of prolonged illness. This finding is found in the study 
of Reddy et al.17, who followed-up four patients with 
persistent symptoms up to 12 months after the disease 
onset. The authors observed that although several markers 
were altered during the acute phase (IL-1b, IL-4, IL-6, 
IL-8, IP-10, MCP-1, MIG, and RANTES), most returned to 
values close to normal in the follow-up. However, MCP-1 
and MIG were persistently elevated in patients during the 
chronic phase, while RANTES levels remained low during 
the acute phase with a tendency to decline even further 
during the chronic phase.
Schilte et al.12 evaluated 20 patients with chronic 
arthralgia 36 months after the onset of the disease, who 
did not have lymphopenia, and the plasma protein levels 
measured by electrophoresis remained within the normal 
range, but the CRP levels were significantly elevated in the 
patients with arthralgia. In addition, the values of factor VII, 
C3, IL-1a and IL-15 were also high in this phase. 
In the present review, around 15% of patients evolved 
to chronification in the studies evaluated, although the 
values obtained cannot be extrapolated to other contexts, 
since the meta-analysis was not designed to specifically 
evaluate the chronification rate. A similar value is cited in 
the literature that points to a percentage of around 14% of 
evolution to chronic arthritis, a symptom evaluated by most 
studies in this review. On the other hand, considering other 
types of manifestations of the disease, the persistence rate 
of nonspecific arthralgia and musculoskeletal symptoms 
can reach 25%30.
In the acute phase, some markers were related to the 
severity of the disease. However, it is important to highlight 
that the severity was classified in a very heterogeneous way 
in the evaluated studies. Ng et al.23 classified as severe, 
patients with temperatures equal to or above 38.5  ºC, 
a heart rate > 100 beats/minute or platelets lower than 
100 x 109 g/L and found a relationship between severity 
and increased levels of IL-1b and IL-6 or reduced levels 
of RANTES. When analyzing these findings, the author 
highlighted that IL-1b and IL-6 are pyrogens and may 
be responsible for the high fever. In addition, IL-1b can 
mediate the development of arthralgia, since these cytokines 
are involved in the pathogenesis of several other forms of 
arthritis, such as rheumatoid arthritis. In turn, RANTES 
is a T-cell chemokine and its main reservoir in peripheral 
blood are platelets, which are typically reduced in CHIK 
infection. CRP was not associated with severity. The study 
by Ng et al.23 evaluated patients in the acute phase and 
found high CRP values in 60% of the patients, but did not 
identify a relationship between the acute phase marker and 
the severity of the disease. 
Lohachanakul et al.25 has also used the same previously 
mentioned criteria, and observed a relationship between high 
concentrations of IL-6 and MCP-1, in addition to low IL-8 
titers with the severity of the disease. The authors point out 
that IL-6 is a potent pyrogen and could mediate joint pain by 
sensitizing the nociceptors in the region, in addition to being 
able to participate in the pain mechanism in local neurons, 
associated with the inflammatory process. The authors 
have also highlighted the role of MCP-1 in the induction 
of monocytes/macrophages, which are involved in the 
pathophysiology of arthritis, in addition to mentioning that 
low levels of IL-8 are consistent with severity of disease, since 
IL-8 fights viral transcription and promotes viral clearance.
Kelvin et al.24 classified the severity of patients 
qualitatively using a questionnaire on the severity of 
symptoms. They observed that patients with high levels 
of MIG, IP-10 and IgG had more severe symptoms, these 
levels had a tendency to decrease, but still remained elevated 
after six months. The high levels of MIG, IP-10 and IL-6 
present in the acute phase are related, by the authors, to a 
possible consequence of the activation of the T cell adaptive 
immunity. In addition, they pointed out that MIG and IP-10 
are chemokines induced by IFN-γ and they participate in 
the regulation of monocyte/macrophage migration, memory 
T cells and NK cells, and can contribute to the persistent 
immune activation in CHIK disease, leading to chronic 
symptoms.
Severity-related biomarkers are also studied in other 
arboviruses, such as dengue, a disease with a clinical 
presentation similar to CHIK fever. The dengue virus 
(DENV)-infected endothelial cells produce chemokine and 
cytokine responses that activate or recruit immune cells 
to the endothelium. The most serious form of the disease, 
the hemorrhagic dengue fever, present a ‘cytokine storm’, 
with high levels of circulating cytokines and chemokines. 
Some studies have shown that elevated levels of IL-6, 
IL-10, IFN-γ, MIF and CCL-4 could be used as potential 
predictors of severity in dengue. Furthermore, increased 
levels of IFN-γ, TNF-α, IL-1β, IL-4, IL-6, IL-7, IL-8, IL10, 
Ferreira et al.
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IL-13, IL-15, IL-17, IL- 18, MIF, CCL2, CCL4, CCL5 and 
IP-10 have been reported in patients with hemorrhagic 
dengue fever, when compared to dengue fever. Thus, factors 
associated with the endothelium, such as the increase in 
Ang-2, vWF, sVCAM, VEGF and VEGFR1 levels, and 
decrease in Ang-1, ADAMTS-13 and VEGFRII levels 
might serve as biomarkers of severity in dengue. Liver 
injury is associated with severe dengue disease with the 
increase in serum aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), gamma-glutamyl transpeptidase, 
alkaline phosphatase and serum albumin concentrations31. 
There are also reports that CRP levels in the early stages 
following the onset of fever may be prognostic for severe 
dengue. Platelets are also mentioned in some studies, and 
platelet associated IgM was suggested to be a predictor 
of hemorrhagic dengue fever. Platelets bind to DENV 
which activates them, this might indicate a coagulation 
response involving DENV immune complexes formation32. 
In comparison with the findings in CHIK fever, some 
interleukins are mentioned in both cases (IL-6 IP-10, 
IL-1β), which may correspond to an initial inflammatory 
phase present in the severe phase of both diseases. The 
studies included in this review do not report on the inclusion 
of biomarkers related to the endothelium to assess their 
relationship with severe forms of CHIK fever; in addition, 
other increased biomarkers such as liver enzymes, CRP 
and the number of platelets were not mentioned in the 
studies as factors related to the severity of CHIKV, however 
few studies have been carried out on the subject, making 
possible to find new biomarkers and parallels with other 
arboviruses according to the advance of research in the area.
It is important to mention that the studies are divergent 
in many key methodological aspects such as: sample size, 
length of follow-up time, stage of the disease at the time 
of blood collection, sample sources and different control 
groups. In addition, the cohorts show significant follow-up 
losses, and samples for the study of biomarkers were taken 
from a very limited number of patients, either because the 
total sample of the studies was already limited, or because 
only a small number of patients underwent more in-depth 
laboratory analysis. The methods of analysis for each 
biomarker has also differed, although the studies have 
shown a good correlation between the ELISA method and 
the Multiplex Cytokine Measurement Kits, often finding 
very close values33, a fact that reduces the chances of bias, 
since these were the main methods cited by the studies.
CONCLUSION
Our study has some limitations. Firstly, we can point 
out the fact that not all studies were included in the meta-
analysis due to the lack of available data. Despite the 
attempts to obtain data from the authors, the feedback 
obtained was low, probably because some articles were 
published a long time ago or because the authors have 
changed their electronic mail addresses and information 
has not been updated, because many of the unexpected 
or undesirable results were not published and bias of 
publication is a concern in all systematic reviews. 
CHIK fever is a public health problem with the 
potential for serious complications. To date, there are no 
widespread exams in the clinical practice of prognostic 
evaluation, in addition, the study of the pathophysiology 
of the disease is fundamental for the development of new 
therapeutic targets. Several biomarkers are cited in the 
literature related to severity (increased levels of IL-6, 
IP-10, IL-1b, MIG, MCP-1 as well as reduced levels of 
RANTES and IL-8) or chronification (increased levels 
of IL-6, TNF-α, MCP-1, IL-12, INF-α14, IL-13, INF-γ, 
GM-CSF, CRP, IL-1a, IL-15, factor VII, IP-10, IL-10, IL-
4, IL-1RA, IL-8, MIP-1α, MIP-1β, ferritin, MIG, ESR, 
NO, malondialdehyde, and reduced levels of RANTES, 
ferritin, eotaxin, HGF, IL-27, IL-17A, IL-29, TGF-β, 
IL-10 and thiols). The search for these biomarkers can 
reveal prognostic factors and important therapeutic targets 
for the treatment of the disease. However, the evaluated 
studies have shown differences and weaknesses that 
make it difficult to compare results. In this sense, more 
standardized studies with larger samples are needed to 
consolidate these findings.
REFERENCES
 1.  Gould E, Pettersson J, Higgs S, Charrel R, Lamballeriea X. 
Emerging arboviruses: why today? One Health. 2017;4:1-13. 
 2.  Lumsden WH. An epidemic of virus disease in Southern Province 
Tanganyika Territory, in 1952-53. II. General description and 
epidemiology. Trans R Soc Trop Med Hyg. 1955;49:33-57.
 3.  Staples JE, Breiman RF, Powers AM. Chikungunya fever: an 
epidemiological review of a re-emerging infectious disease. 
Clin Infect Dis. 2009;49:942-8.
 4.  Faria NR, Lourenco J, Cerqueira EM, Lima MM, Pybus O, 
Alcantara LC. Epidemiology of Chikungunya virus in Bahia, 
Brazil, 2014-2015. PLoS Curr. 2016;1:1-8.
 5.  Sharma SK, Jain S. Chikungunya: a rheumatologist’s perspective. 
Int J Rheum Dis. 2018;21:584-601. 
 6.  Brito CA. Alert: severe cases and deaths associated with 
Chikungunya in Brazil. Rev Soc Bras Med Trop. 2017;50:585-
9.
 7.  Chirathaworn C, Poovorawan Y, Lertmaharit S, Wuttirattanakowit 
N. Cytokine levels in patients with Chikungunyavirus infection. 
Asian Pac J Trop Med. 2013;6:631-4. 
Rev Inst Med Trop São Paulo. 2021;63:e16
Biomarkers of severity and chronification in chikungunya fever: a systematic review and meta-analysis
Page 11 of 11
 8.  Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting 
items for systematic reviews and meta-analyses: the PRISMA 
Statement. Ann Intern Med. 2009;151:264-9.
 9.  von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, 
Vandenbroucke JP. The strengthening the reporting of 
observational studies in epidemiology (STROBE) statement: 
guidelines for reporting observational studies. Int J Surg. 
2014;12:1495-9.
 10.  Venugopalan A, Ghorpade RP, Chopra A. Cytokines in acute 
Chikungunya. PLoS One. 2014;9:e111305.
 11.  Chaaitanya IK, Muruganandam N, Sundaram SG, Kawalekar O, 
Sugunan AP, Manimunda SP, et al. Role of proinflammatory 
cytokines and chemokines in chronic arthropathy in 
Chikungunya infection. Viral Immunol. 2011;24:265-71. 
 12.  Schilte C, Staikovsky F, Couderc T, Madec Y, Carpentier F, 
Kassab S, et al. Chikungunya virus-associated long-term 
arthralgia: a 36-month prospective longitudinal study. PLoS 
One. 2013;7:e2137.
 13.  Win MK, Chow A, Dimatatac F, Go CJ, Leo YS. Chikungunya 
fever in Singapore: acute clinical and laboratory features, 
and factors associated with persistent arthralgia. J Clin Virol. 
2010;49:111-4.
 14.  Hoarau JJ, Bandjee MC, Trotot PK, Das T, Li-Pat-Yuen G, Dassa 
B, et al. Persistent chronic inflammation and infection by 
Chikungunya arthritogenic response alphavirus in spite of a 
robust host immune response. J Immunol. 2010;184:5914-27.
 15.  Chopra A, Venugopalan A. Persistent rheumatic musculoskeletal 
pain and disorders at one year post-Chikungunya epidemic in 
south Maharashtra: a rural community based observational 
study with special focus on naive persistent rheumatic 
musculoskeletal cases and selected cytokine expression. Indian 
J Rheumatol. 2011;6 Suppl:5-11.
 16.  Chow A, Her Z, Ong EK, Chen J, Dimatatac F, Kwek DJ, et al. 
Persistent arthralgia induced by Chikungunya virus infection 
is associated with interleukin-6 and granulocyte macrophage 
colony-stimulating factor. J Infect Dis. 2011;203:149-57.
 17.  Reddy V, Mani RS, Desai A, Vasanthapuram R. Correlation 
of plasma viral loads and presence of Chikungunya IgM 
antibodies with cytokine/chemokine levels during acute 
Chikungunya virus infection. J Med Virol. 2014;86:1393-401.
 18.  Anfasa F, Provacia L, GeurtsvanKessel C, Wever R, Gerstenbluth 
I, Osterhaus AD, et al. Hyperferritinemia is a potential marker 
of chronic Chikungunya: a retrospective study on the Island 
of Curacao during the 2014–2015 outbreak. J Clin Virol. 
2017;86:31-8.
 19.  Sepúlveda-Delgado J, Vera-Lastra OL, Trujillo K, Canseco-
Ávila LM, Sánchez-González RA, Gómez-Cruz O, et al. 
Inflammatory biomarkers, disease activity index, and self-
reported disability may be predictors of chronic arthritis 
after Chikungunya infection: brief report. Clin Rheumatol. 
2017;36:695-9.
 20.  Cavalcanti NG, Vilar KM, Duarte AL, Rêgo MJ, Pereira MC, Pitta 
IR, et al. IL-27 in patients with Chikungunya fever: a possible 
chronicity biomarker? Acta Trop. 2019;196:48-51.
 21.  Banerjee N, Mukhopadhyay S. Oxidative damage markers and 
inflammatory cytokines are altered in patients suffering with 
post-chikungunya persisting polyarthralgia. Free Radic Res. 
2018;52:887-95.
 22.  Chopra A, Anuradha V, Ghorpade R, Saluja M. Acute 
Chikungunya and persistent musculoskeletal pain following the 
2006 Indian epidemic: a 2-year prospective rural community 
study. Epidemiol Infect. 2012;140:842-50.
 23.  Ng LF, Chow A, Sun YJ, Kwek DJ, Lim PL, Dimatatac F, et al. 
IL-1b, IL-6, and RANTES as biomarkers of Chikungunya 
severity. PLoS One. 2009;4:e4261.
 24.  Kelvin AA, Banner D, Silvi G, Moro ML, Spataro N, Gaibani 
P, et al. Inflammatory cytokine expression is associated with 
Chikungunya virus resolution and symptom severity. PLoS 
Negl Trop Dis. 2011;5:e1279.
 25.  Lohachanakul J, Phuklia W, Thannagith M, Thonsakulprasert 
T, Ubol S. High concentrations of circulating interleukin-6 
and monocyte chemotactic protein-1 with low concentrations 
of interleukin-8 were associated with severe Chikungunya 
fever during the 2009-2010 outbreak in Thailand. Microbiol 
Immunol. 2012;56:134-8.
 26.  Jain J, Nayak K, Tanwar N, Gaind R, Gupta B, Shastri JS, et 
al. Clinical, serological, and virological analysis of 572 
Chikungunya patients from 2010 to 2013 in India. Clin Infect 
Dis. 2017;65:133-40.
 27.  Palomino DC, Marti LC. Chemokines and immunity. Einstein 
(Sao Paulo). 2015;13:469-73.
 28.  Tanabe IS, Tanabe EL, Santos EC, Martins WV, Araújo IM, 
Cavalcante MC, et al. Cellular and molecular immune response 
to Chikungunya virus infection. Front Cell Infect Microbiol. 
2018;8:345.
 29.  Bradley JR.TNF-mediated inflammatory disease. J Pathol. 
2008;214:149-60.
 30.  Rodríguez-Morales AJ, Cardona-Ospina JA, Urbano-Garzon SF, 
Hurtado-Zapata JS. Prevalence of post-Chikungunya infection 
chronic inflammatory arthritis: a systematic review and meta-
analysis. Arthritis Care Res (Hoboken). 2016;68:1849-58. 
 31.  John DV, Lin YS, Perng GC. Biomarkers of severe dengue disease: 
a review. J Biomed Sci. 2015;22:83.
 32.  Rathore AP, Faroukv FS, St. John AL. Risk factors and biomarkers 
of severe dengue. Curr Opin Virol. 2020;43:1-8
 33.  Richens JL, Urbanowicz RA, Metcalf R, Corne J, O’Shea P, 
Fairclough L. Quantitative validation and comparison of 
multiplex cytokine kits. J Biomol Screen. 2010;15:562-8.
